Immunomedics Inc (IMMU) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access IMMU quarterly Cash Flow →
The cash flow figures below highlight longer-term patterns in how Immunomedics Inc manages cash inflows and outflows over time.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2019)
12 Months
(Jun 30 2018) (Jun 30 2017) (Jun 30 2016) (Jun 30 2015)
Operating Activities
Income-157.75
Depreciation & amortization2.10
Amortization of Other Assets0.18
Increase (Decrease) in Insurance Assets0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.89
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-1.40
Licenses Revenue-
Gain On Business Interruption Insurance Recovery-
Investment Income Amortization Of Discount-
Gain Loss On Sale Of Auction Rate Securities-
Amortization Of Deferred Revenue-
Amortization Of Deferred Revenue-
Share Based Compensation Before Adjustment Of Stock Plan Activity-
Warrant Related Expense-
Interest Expense Debt19.29
Loss On Induced Exchanges Of Debt0.90
Non Recourse Debt Increase Accrued Interest-
Operating Lease Expense-
Income taxes0.00
Gain (Loss) on Sale of Securities, Net0.00
Increase (Decrease) in Accounts Receivable0.05
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.44
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets3.75
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.09
Discontinued operations0.00
Net Cash flow from Operating Activities-130.66
Investing Activities
Capital Expenditures-11.21
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities21.82
Payments to Acquire Available-for-sale Securities0.00
Real Estate Investments0.00
Proceeds From Partial Liquidation Of Life Insurance Policy-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Insurance Settlement, Investing Activities0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities10.61
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.86
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-637.35
Payments For Repurchase Of Common Stock And Other Stock Option Activity-
Payment Of Debt Conversion Fees-
Debt Conversion Original Debt Amount13.76
Capital Expenditures Incurred But Not Yet Paid0.80
Reclass Of Warrant Liability To Capital Contributed In Excess Of Par7.57
Stock Issued2.45
Restricted Cash And Cash Equivalents At Carrying Value-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents612.58
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.67
Effect of exchange rate on cash flow-0.02
Discontinued operations0.00
Free Cash Flow-141.88
Total Cash Flow-118.41
4 historic quarters locked

Sign in to unlock the full Immunomedics Inc cash flow history.

About IMMU Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License